Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

323 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions.
Handunnetti SM, Anderson MA, Burbury KI, Thompson PA, Burke G, Bressel M, Di Iulio JL, Hicks RJ, Westerman DA, Lade S, Pott C, Agarwal R, Koldej RM, Ritchie D, Dreyling M, Dawson MA, Dawson SJ, Seymour JF, Roberts AW, Tam CS. Handunnetti SM, et al. Among authors: tam cs. Blood. 2024 Apr 25:blood.2023023388. doi: 10.1182/blood.2023023388. Online ahead of print. Blood. 2024. PMID: 38662991
Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: post-hoc analysis of a large clinical trial safety database.
Brown JR, Ghia P, Jurczak W, Kahl BS, Lamanna N, Robak T, Shadman M, Tam CS, Qiu L, Paik J, Salmi T, Wang L, Zhang J, Zhang M, Cohen A, Ma H, Tedeschi A. Brown JR, et al. Among authors: tam cs. Haematologica. 2024 Feb 29. doi: 10.3324/haematol.2023.283846. Online ahead of print. Haematologica. 2024. PMID: 38426293 Free article. No abstract available.
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.
Tam CS, Opat S, D'Sa S, Jurczak W, Lee HP, Cull G, Owen RG, Marlton P, Wahlin BE, García-Sanz R, McCarthy H, Mulligan S, Tedeschi A, Castillo JJ, Czyż J, Fernández De Larrea C, Belada D, Libby E, Matous J, Motta M, Siddiqi T, Tani M, Trněný M, Minnema MC, Buske C, Leblond V, Treon SP, Trotman J, Wu B, Yu Y, Shen Z, Chan WY, Schneider J, Allewelt H, Cohen A, Dimopoulos MA. Tam CS, et al. Blood Adv. 2024 Apr 9;8(7):1639-1650. doi: 10.1182/bloodadvances.2023010906. Blood Adv. 2024. PMID: 38315878 Free PMC article.
Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon.
Lew TE, Bennett R, Lin VS, Whitechurch A, Handunnetti SM, Marlton P, Shen Y, Mulligan SP, Casan J, Blombery P, Tam CS, Roberts AW, Seymour JF, Thompson PA, Anderson MA. Lew TE, et al. Among authors: tam cs. Blood Adv. 2024 Mar 26;8(6):1439-1443. doi: 10.1182/bloodadvances.2023011327. Blood Adv. 2024. PMID: 38231032 Free PMC article. No abstract available.
Australia and New Zealand consensus position statement: use of COVID-19 therapeutics in patients with haematological malignancies.
Campbell A, Teh B, Mulligan S, Ross DM, Weinkove R, Gilroy N, Gangatharan S, Prince HM, Szer J, Trotman J, Lane S, Dickinson M, Quach H, Enjeti AK, Ku M, Gregory G, Hapgood G, Ho PJ, Cochrane T, Cheah C, Greenwood M, Latimer M, Berkahn L, Wight J, Armytage T, Diamond P, Tam CS, Hamad N. Campbell A, et al. Among authors: tam cs. Intern Med J. 2024 Feb;54(2):328-336. doi: 10.1111/imj.16303. Epub 2023 Dec 25. Intern Med J. 2024. PMID: 38146232
Reply to Y. Song et al.
Dimopoulos MA, Opat S, Treon SP, Tam CS. Dimopoulos MA, et al. Among authors: tam cs. J Clin Oncol. 2024 Feb 1;42(4):482-484. doi: 10.1200/JCO.23.02162. Epub 2023 Dec 4. J Clin Oncol. 2024. PMID: 38048515 No abstract available.
Cognition following chimeric antigen receptor T-cell therapy: A systematic review.
Kazzi C, Kuznetsova V, Siriratnam P, Griffith S, Wong S, Tam CS, Alpitsis R, Spencer A, O'Brien TJ, Malpas CB, Monif M. Kazzi C, et al. Among authors: tam cs. J Autoimmun. 2023 Oct 12;140:103126. doi: 10.1016/j.jaut.2023.103126. Online ahead of print. J Autoimmun. 2023. PMID: 37837807 Free article. Review.
323 results